. . "# Dittrich HC, Gupta DK, Hack TC, Dowling T, Callahan J, Thomson S: The effect of KW-3902, an adenosine A1 receptor antagonist, on renal function and renal plasma flow in ambulatory patients with heart failure and renal impairment. J Card Fail. 2007 Oct;13(8):609-17. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17923351"@en . . . . . . . . . "Investigated for use/treatment in congestive heart failure and kidney disease."@en . . . "KW-3902 (rolofylline),is an adenosine A1-receptor antagonist, on diuresis and renal function compared with placebo in patients with acute decompensated heart failure (ADHF). Plasma adenosine levels are elevated in patients with heart failure and adenosine A1 receptors in the kidney mediate vasoconstriction of afferent arterioles, reabsorption of sodium and water in proximal tubules, and tubuloglomerular feedback in the juxtaglomerular apparatus. Accordingly, inhibition of these receptors would be expected to increase renal blood flow and enhance diuresis. The effects of KW-3902 on renal function are consistent with those obtained with another adenosine A1-receptor antagonist in both experimental and human heart failure."@en . . . "KW-3902 is a compounds that is under clinical development by pharmaceutical company, NovaCardia. It is used for the treatment of congestive heart failure."@en . . . . . . . "KW-3902"@en . . . . . . . . . "investigational"@en . . . .